vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

vTv Therapeutics (Nasdaq: VTVT) granted 12,500 stock options to two non-executive employees as a material inducement to employment under Nasdaq Listing Rule 5635(c)(4).

Rhea-AI Summary

vTv Therapeutics (Nasdaq: VTVT) granted 12,500 stock options to two non-executive employees as a material inducement to employment under Nasdaq Listing Rule 5635(c)(4).

The options have a weighted average exercise price of $34.15, vest over 4 years, carry a 10-year term, and are issued under the 2026 Inducement Plan.

Argus Jul 6 session

-2.43% close to close Open Argus

Details

News Market Reaction – VTVT

In the Jul 6 session, VTVT declined 2.43%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The company granted 12,500 stock options at a weighted average exercise price of $34.15 under its 20...

Analysis

The company granted 12,500 stock options at a weighted average exercise price of $34.15 under its 2026 Inducement Plan, a routine employment incentive that modestly expands equity overhang alongside capacity available under its effective S-3 shelf registration.

Key Figures

Inducement stock options: 12,500 options Exercise price: $34.15 per share Initial vesting cliff: 25% after 1 year +3 more

Inducement stock options

12,500 options

Granted to two non-executive employees as material inducement

Exercise price

$34.15 per share

Weighted average exercise price of granted options

Initial vesting cliff

25% after 1 year

Portion of options vesting on one-year anniversary

Remaining vesting period

36 months

Quarterly vesting of remaining options following first year

Total vesting duration

4 years

Overall vesting schedule for inducement options

Option term

10 years

Contractual life of the inducement stock options

Historical Context

5 past events · Latest: Jun 02

5 events

1. Jun 02

   Inducement option grant

   24h Move

   -0.2%

   Small stock option inducement grant to a new employee under Nasdaq rules.

2. May 13

   Earnings report

   24h Move

   +21.4%

   Q1 2026 revenue and net income driven by licensing payments and strong cash.

3. May 08

   Inducement option grant

   24h Move

   -0.7%

   Inducement stock options for non-executive employees under the 2026 plan.

4. May 07

   Conference participation

   24h Move

   -2.0%

   Announcement of participation in May 2026 investor conferences and webcasts.

5. Apr 07

   Inducement option grant

   24h Move

   +0.6%

   Grant of stock options to a non-executive employee under inducement plan.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

nasdaq listing rule 5635(c)(4)

1 terms

nasdaq listing rule 5635(c)(4) regulatory

"as a material inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

HIGH POINT, N.C., July 02, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today announced that it granted 12,500 stock options to purchase shares of common stock to two non-executive employees as a material inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4).

The stock options that were granted have a weighted average exercise price of $34.15 per share. Each option award will vest over a 4-year period, with 25% of the shares underlying the option vesting on the one-year anniversary of the applicable vesting commencement date and the remaining shares thereafter vesting quarterly over the following 36 months, subject to continued employment with vTv on such vesting dates. The options have a term of 10 years and are subject to the terms and conditions of the 2026 Inducement Plan and the stock option agreement covering the grant.

About vTv Therapeutics
vTv Therapeutics is a late-stage biopharmaceutical company focused on developing oral, small molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. vTv’s clinical pipeline is led by cadisegliatin, currently in a US Phase 3 trial, a potential first-in-class oral glucokinase activator being investigated for the treatment of type 1 diabetes. vTv and its development partners are investigating multiple molecules across different indications for chronic diseases. Learn more at vtvtherapeutics.com or follow the company on LinkedIn or X.

About Cadisegliatin
Cadisegliatin (TTP399) is a novel, oral small molecule, liver-selective glucokinase activator being investigated in the US as a potential first-in-class oral adjunctive treatment for type 1 diabetes (T1D). In non-clinical studies, cadisegliatin acted selectively on the liver and increased the activity of glucokinase independently from insulin. These studies support clinical investigation of whether cadisegliatin can improve glycemic control through hepatic glucose uptake and glycogen storage. Cadisegliatin has been granted Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA).

Cadisegliatin is under investigation, and the safety and efficacy have not been established. There is no guarantee that this product will receive health authority approval or become commercially available for the use being investigated.

Investor Contact
John Fraunces
LifeSci Advisors, LLC
jfraunces@lifesciadvisors.com

Media Contact
Caren Begun
TellMed Strategies
201-396-8551
caren.begun@tmstrat.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What inducement stock options did vTv Therapeutics (VTVT) grant on July 2, 2026?

vTv Therapeutics granted 12,500 inducement stock options to two non-executive employees. According to vTv Therapeutics, these options are a material inducement to employment and are issued under Nasdaq Listing Rule 5635(c)(4).

What is the exercise price of the new vTv Therapeutics (VTVT) inducement options?

The inducement stock options have a weighted average exercise price of $34.15 per share. According to vTv Therapeutics, these options allow employees to purchase common stock at this exercise price over the option term.

How do vTv Therapeutics (VTVT) inducement stock options vest for the new employees?

The options vest over four years, with 25% vesting after one year and the rest quarterly. According to vTv Therapeutics, continued employment on each vesting date is required for remaining shares to vest.

What is the term of the vTv Therapeutics (VTVT) inducement stock options granted in 2026?

The inducement stock options have a 10-year term from the grant date. According to vTv Therapeutics, the options remain subject to the 2026 Inducement Plan and the applicable stock option agreement.

Under which plan were the July 2026 vTv Therapeutics (VTVT) inducement options granted?

The July 2026 inducement options were granted under the 2026 Inducement Plan. According to vTv Therapeutics, each option is also governed by a stock option agreement covering the terms of the grant.